The Peripheral Blood Lymphocyte Subsets as Predicative Biomarkers Reflecting the Efficacy and Toxicity in Patients With Locally Advanced Non-small Cell Lung Cancer Received Chemoradiotherapy With or Without Immunotherapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Adverse Event
研究概览
简要总结
This study is a prospective cohort study to evaluate the peripheral blood lymphocyte subsets as predicative biomarkers reflecting the efficacy and toxicity in patients with locally advanced non-small cell lung cancer (NSCLC) received chemoradiotherapy (CRT) with or without immune checkpoint inhibitors (ICIs).
详细描述
All patients had a pathologically confirmed locally advanced NSCLC according to the 8th AJCC staging system and received definitive radiotherapy, concurrently or sequentially combined with platinum-based doublet chemotherapy. The peripheral blood samples at various time points including before radiation, 4 weeks after beginning of radiation, the end of radiation, 1 month post radiation, and 1 month post consolidation immunotherapy were collected for lymphocyte subsets detection.
The subjects will be divided into two groups according to whether patients received ICIs, namely, NSCLC patients received CRT plus ICIs and NSCLC patients received CRT.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years; ECOG score 0-
- •Pathologically confirmed locally advanced NSCLC according to the 8th AJCC staging system.
- •Received definitive radiotherapy, concurrently or sequentially combined with platinum-based doublet chemotherapy.
- •No serious medical diseases and dysfunction of major organs, such as blood routine, liver, kidney, heart and lung function.
排除标准
- •Pathologic type was adenocarcinoma with EGFR gene mutation or ALK gene rearrangement.
- •Patients with other active malignancies within 5 years or at the same time.
- •Active or previously documented autoimmune or inflammatory diseases (including inflammatory bowel disease, diverticulitis [except diverticular disease], systemic lupus erythematosus, Sarcoidosis syndrome, Wegener' s syndrome).
- •History of allogeneic organ transplantation.
- •History of active primary immunodeficiency.
- •Patients with uncontrolled concurrent diseases, including but not limited to persistent or active infection (including tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus, etc.), symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled arrhythmia, active interstitial lung disease, severe chronic gastrointestinal disease with diarrhea or mental illness.
- •Women of child-bearing potential who are pregnant or breastfeeding.
- •The investigator judged other situations not suitable for inclusion in this study.
研究组 & 干预措施
NSCLC patients received CRT plus ICIs
For it's an observational study, locally advanced NSCLC patients received CRT with induction immunotherapy or consolidation immunotherapy will be divided into the group "NSCLC patients received CRT plus ICIs".
干预措施: concurrent or sequential chemoradiotherapy (Radiation)
NSCLC patients received CRT plus ICIs
For it's an observational study, locally advanced NSCLC patients received CRT with induction immunotherapy or consolidation immunotherapy will be divided into the group "NSCLC patients received CRT plus ICIs".
干预措施: Immunotherapy (Drug)
NSCLC patients received CRT
For it's an observational study, locally advanced NSCLC patients received CRT without immunotherapy will be divided into the group "NSCLC patients received CRT".
干预措施: concurrent or sequential chemoradiotherapy (Radiation)
结局指标
主要结局
Adverse Event
时间窗: AEs and SAEs must be collected from the start of treatment to 28 days after discontinuation of study drug, up to 24 months.
The incidence of adverse events (AEs) and serious adverse events (SAEs) is evaluated by CTCAE 5.0. Appropriate description of AEs and laboratory data/vital signs will be produced. Number of patients who had at least one adverse event will be calculated.
次要结局
- Progression-free survival (PFS)(From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.)
- Overall survival (OS)(From the date of first treatment to the date of any documented death due to any cause, assessed up to 24 months.)
- Objective Response Rate (ORR)(Tumor assessment using RECIST will be performed at baseline then every 3 months from the first treatment until objective progression or death from any cause, assessed up to 24 months.)
- Disease control rate (DCR)(Tumour assessment using RECIST will be performed at baseline then every 3 months from first treatment until objective progression or death from any cause, assessed up to 24 months.)